21
Apr

Alnylam’s lead RNAi treatment continued to prevent nerve damage tied to a rare disease in an ongoing Phase II study, paving the path for late-stage development.

…read more

Source: Alnylam’s star RNAi drug keeps the pace on the way to Phase III

    

0 No comments